Key result
The 2.5% of ACS patients without standard modifiable risk factors received less reperfusion therapy but had similar 12-month rates of new ACS and death compared to those with risk factors.
Why the study?
Patients increasingly present with ACS without standard modifiable risk factors, yet their treatment remains empirical, prompting evaluation of how SMuRF absence affects hospital management and outcomes.
Does the absence of standard modifiable risk factors affect hospital management and outcomes in patients with acute coronary syndrome?
Observational (n=2,718)
Does the absence of standard modifiable risk factors affect hospital management and outcomes in patients with acute coronary syndrome?
ACS patients without standard modifiable risk factors receive less aggressive treatment (reperfusion, DAPT) but have a similar 12-month prognosis for death and recurrent ACS compared to those with risk factors.
Answers are grounded in this paper and cite their sources.
SMuRF-less ACS patients may face treatment disparities; leaves open whether tailored approaches improve outcomes.
BACKGROUND: It is increasingly recognized that patients might suffer from acute coronary syndrome (ACS) in the absence of standard modifiable risk factors (SMuRFs). Their treatment remains largely empirical and follows the same principles for counterparts with SMuRFs. We examined whether the absence of SMuRFs affect hospital management and outcomes. METHODS: CALLINICUS-Hellas Registry is an observational prospective study evaluating the adherence to lipid-lowering therapy among ACS patients. Two groups were created according to SMuRF status. The patients were followed for 12 months after hospital discharge and the study's endpoints were the development of new ACS, cardiac death and non-cardiac death. RESULTS: A total of 2718 consecutive patients with ACS were included and 68 cases (2.5%) were SMuRF-less. LDL-cholesterol, triglycerides and waist circumference were higher among patients with SMuRFs. SMuRF-less patients were more likely to have one vessel or non-obstructive coronary artery disease and less likely to receive reperfusion or dual antiplatelet therapy. On the contrary non-cardiac death, cardiac death and new ACS did not differ between groups. B-blockers and ACEi/ARB were equally prescribed between groups, yet patients with SMuRFs were more likely to receive ezetimibe combined with high intensity statins at discharge. SMuRF-less patients were more likely to attain lower LDL-cholesterol levels after 12 months of follow up and to achieve values below 55 mg/dl. CONCLUSION: SMuRF status is associated with treatment disparities among contemporary ACS patients, and the absence of traditional risk factors does not dictate benign prognosis.
No takes yet. Share an insight, caveat, or question.
Papathanasiou et al. (2026) conducted an observational in Acute coronary syndrome (ACS) (n=2,718). Absence of standard modifiable risk factors (SMuRF-less) vs. Presence of standard modifiable risk factors (SMuRFs) was evaluated on Development of new ACS, cardiac death and non-cardiac death. The 2.5% of ACS patients without standard modifiable risk factors received less reperfusion therapy but had similar 12-month rates of new ACS and death compared to those with risk factors.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: